Truncated recombinant human SP-D attenuates emphysema and type II cell changes in SP-D deficient mice
Open Access
- 3 October 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Respiratory Research
- Vol. 8 (1), 70
- https://doi.org/10.1186/1465-9921-8-70
Abstract
Background Surfactant protein D (SP-D) deficient mice develop emphysema-like pathology associated with focal accumulations of foamy alveolar macrophages, an excess of surfactant phospholipids in the alveolar space and both hypertrophy and hyperplasia of alveolar type II cells. These findings are associated with a chronic inflammatory state. Treatment of SP-D deficient mice with a truncated recombinant fragment of human SP-D (rfhSP-D) has been shown to decrease the lipidosis and alveolar macrophage accumulation as well as production of proinflammatory chemokines. The aim of this study was to investigate if rfhSP-D treatment reduces the structural abnormalities in parenchymal architecture and type II cells characteristic of SP-D deficiency. Methods SP-D knock-out mice, aged 3 weeks, 6 weeks and 9 weeks were treated with rfhSP-D for 9, 6 and 3 weeks, respectively. All mice were sacrificed at age 12 weeks and compared to both PBS treated SP-D deficient and wild-type groups. Lung structure was quantified by design-based stereology at the light and electron microscopic level. Emphasis was put on quantification of emphysema, type II cell changes and intracellular surfactant. Data were analysed with two sided non-parametric Mann-Whitney U-test. Main Results After 3 weeks of treatment, alveolar number was higher and mean alveolar size was smaller compared to saline-treated SP-D knock-out controls. There was no significant difference concerning these indices of pulmonary emphysema within rfhSP-D treated groups. Type II cell number and size were smaller as a consequence of treatment. The total volume of lamellar bodies per type II cell and per lung was smaller after 6 weeks of treatment. Conclusion Treatment of SP-D deficient mice with rfhSP-D leads to a reduction in the degree of emphysema and a correction of type II cell hyperplasia and hypertrophy. This supports the concept that rfhSP-D might become a therapeutic option in diseases that are characterized by decreased SP-D levels in the lung.Keywords
This publication has 43 references indexed in Scilit:
- A brief update on lung stereologyJournal of Microscopy, 2006
- Surfactant protein D in human lung diseasesEuropean Journal of Clinical Investigation, 2006
- Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluidEuropean Respiratory Journal, 2004
- GM-CSF mediates alveolar epithelial type II cell changes, but not emphysema-like pathology, in SP-D-deficient miceAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Total number and mean size of alveoli in mammalian lung estimated using fractionator sampling and unbiased estimates of the Euler characteristic of alveolar openingsThe Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, 2004
- Structural Requirements for SP-D Function in vitro and in vivo: Therapeutic Potential of Recombinant SP-DImmunobiology, 2002
- Reversibility of Pulmonary Abnormalities by Conditional Replacement of Surfactant Protein D (SP-D) in VivoPublished by Elsevier BV ,2002
- Surfactant Proteins A and D and Pulmonary Host DefenseAnnual Review of Physiology, 2001
- The unbiased estimation of number and sizes of arbitrary particles using the disectorJournal of Microscopy, 1984
- Internal surface area and other measurements in emphysemaThorax, 1967